NCT05030675 2025-02-13
Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents
M.D. Anderson Cancer Center
Phase 1 Completed
Clinical Trials
10 trialsNCT03246074 2024-10-24
Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT02077192 2023-12-11
Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
Rigel Pharmaceuticals
Phase 3 Completed
NCT02611063 2023-03-17
Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant
Duke University
Phase 1 Completed
NCT02076399 2019-02-12
FIT
Rigel Pharmaceuticals
Phase 3 Completed
NCT02076412 2019-01-25
FIT
Rigel Pharmaceuticals
Phase 3 Completed
NCT00446095 2016-09-19
Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma
Rigel Pharmaceuticals
Phase 1/2 Completed
NCT00798096 2016-09-19
Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma
Rigel Pharmaceuticals
Phase 2 Completed
NCT00923481 2015-09-30
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01499303 2014-08-22
Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
AstraZeneca
Phase 2 Completed